The fully human anti-CD30 antibody 5F11 activates NF-κB and sensitizes lymphoma cells to bortezomib-induced apoptosis

Blood

Volumn 106, Issue 5, 2005, Pages 1839-1842

  Böll, Boris ^a   Hansen, Hinrich ^a   Heuck, Friederike ^a   Reiners, Katrin ^a   Borchmann, Peter ^a   Rothe, Achim ^a   Engert, Andreas ^a   Von Strandmann, Elke Pogge ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CD30 ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 5F11; PROTEASOME INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER MODEL; CELL DEATH; CELL KILLING; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; DRUG SENSITIZATION; HODGKIN DISEASE; HUMAN; HUMAN CELL; LYMPHOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

EID: 23944469381     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2005-01-0427     Document Type: Article

References (20)

1. Schneider C, Hubinger G. Pleiotropic signal transduction mediated by human CD30: a member of the tumor necrosis factor receptor (TNFR) family. Leuk Lymphoma. 2002;43:1355-1366.
2. Levi E, Pfeifer WM, Kadin ME. CD30-activation-mediated growth inhibition of anaplastic large-cell lymphoma cell lines: apoptosis or cell-cycle arrest? Blood. 2001;98:1630-1632.
3. Mir SS, Richter BW, Duckett CS. Differential effects of CD30 activation in anaplastic large cell lymphoma and Hodgkin disease cells. Blood. 2000;96:4307-4312.
4. Borchmann P, Treml JF, Hansen H, et al. The human anti-CD30 antibody 5F11 shows in vitro and in vivo activity against malignant lymphoma. Blood. 2003;102:3737-3742.
5. Wahl AF, Klussman K, Thompson JD, et al. The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease. Cancer Res. 2002;62:3736-3742.
6. Izban KF, Ergin M, Huang Q, et al. Characterization of NF-kappaB expression in Hodgkin's disease: inhibition of constitutively expressed NF-kappaB results in spontaneous caspase-independent apoptosis in Hodgkin and Reed-Stemberg cells. Mod Pathol. 2001;14:297-310.
7. Horie R, Higashihara M, Watanabe T. Hodgkin's lymphoma and CD30 signal transduction. Int J Hematol. 2003;77:37-47.
8. Horie R, Watanabe T, Morishita Y, et al. Ligand-independent signaling by overexpressed CD30 drives NF-kappaB activation in Hodgkin-Reed-Stemberg cells. Oncogene. 2002;21:2493-2503.
9. Heuck F, Ellermann J, Borchmann P, et al. Combination of the human ani-CD30 antibody 5F11 with cytostatic drugs enhances its antitumor activity against Hodgkin and anaplastic large cell lymphoma cell lines. J Immunother. 2004;27:347-353.
10. Dong L, Hulsmeyer M, Durkop H, et al. Human CD30: structural implications from epitope mapping and modeling studies. J Mol Recognit. 2003;16:28-36.
11. Kreuz S, Siegmund D, Scheurich P, Wajant H. NF-kappaB inducers upregulate cFLIP, a cycloheximide-sensitive inhibitor of death receptor signaling. Mol Cell Biol. 2001;21:3964-3973.
12. Kim KW, Kim BJ, Chung CW, et al. Caspase cleavage product lacking amino-terminus of IkappaBalpha sensitizes resistant cells to TNF-alpha and TRAIL-induced apoptosis. J Cell Biochem. 2002;85:334-345.
13. Mathas S, Lietz A, Anagnostopoulos I, et al. cFLIP mediates resistance of Hodgkin/Reed-Sternberg cells to death receptor-induced apoptosis. J Exp Med. 2004;199:1041-1052.
14. Thomas RK, Kallenborn A, Wickenhauser C, et al. Constitutive expression of c-FLIP in Hodgkin and Reed-Sternberg cells. Am J Pathol. 2002;160:1521-1528.
15. Dutton A, O'Neil JD, Milner AE, et al. Expression of the cellular FLICE-inhibitory protein (c-FLIP) protects Hodgkin's lymphoma cells from autonomous Fas-mediated death. Proc Natl Acad Sci USA. 2004;101:6611-6616.
16. Guzman ML, Swiderski CF, Howard DS, et al. Preferential induction of apoptosis for primary human leukemic stem cells. Proc Natl Acad Sci U S A. 2002;99:16220-16225.
17. Zheng B, Georgakis GV, Li Y, et al. Induction of cell cycle arrest and apoptosis by the proteasome inhibitor PS-341 in Hodgkin disease cell lines is independent of inhibitor of nuclear factor-kappaB mutations or activation of the CD30, CD40, and RANK receptors. Clin Cancer Res. 2004;10:3207-3215.
18. O'Connor OA, Wright J, Moskowitz C, et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol. 2005;23:676-684.
19. Strauss S, Maharaj L, Stec J, et al. Phase II clinical study of bortezomib (VELCADE) in patients with relapsed/refractory Non-Hodgkin's Lymphoma (NHL) and Hodgkin's disease (HD) [abstract]. Blood. 2004;104:389a. Abstract 1386.
20. Younes A, Pro B, Romaguera J, et al. Safety and efficacy of bortezomib (Velcade) for the treatment of relapsed classical Hodgkin's disease [abstract]. Blood. 2004;104:722a. Abstract 2638.